Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension

A Randomized, Double-blind, Double-dummy, Multicenter Clinical Trial to Evaluate the Additional Efficacy and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension, Who Fail to Attain the Blood Pressure Goals With Olmesartan Medoxomil 20mg Monotherapy

This study is designed to evaluate the additional efficacy and safety of olmesartan medoxomil/hydrochlorothiazide in the treatment of Chinese patients with mild to moderate essential hypertension, who fail to attain the blood pressure goals with olmesartan medoxomil monotherapy

Inclusion Criteria:

• At Visit 3, mean seated diastolic blood pressure (SeDBP) ≥ 95 mmHg and < 110 mmHg, AND mean seated systolic blood pressure (SeSBP) ≥140 mmHg and < 180 mmHg
• At Visit 4, mean SeDBP ≥ 90 mmH
• No significant disorder in blood, kidney, liver, cardiovascular system or endocrinology system

Exclusion Criteria:

• Patients with known or suspect secondary hypertension
• Unstable angina
• History of acute myocardial infarct, or PTCA or surgical cardiac procedures 3 months before entry into this study
• Prior or current congestive heart failure (NYHA grade III or IV), hypertrophic obstructive cardiomyopathy, valvular disease or rheumatic heart disease
• Arrhythmia of clinical significance
• Bilateral renal artery stenosis, isolated renal artery stenosis, post kidney transplantation
• Acute glomerular nephritis
• Gout sufferers, even with the normal serum uric acid at entry
• Retinal hemorrhage /exudate
• Type 1 diabetes mellitus
• Uncontrolled type 2 diabetes mellitus
• Hypovolemia
• Patients with autoimmune disease